Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1770-1779

  Niegisch, Günter ^a   Knievel, Judith ^a   Koch, Annemarie ^a   Hader, Christiane ^a   Fischer, Ute ^a   Albers, Peter ^a   Schulz, Wolfgang A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Epigenetic; HDAC inhibitor; Histone deacetylase; Targeted therapy; Urothelial cancer

Indexed keywords

CASPASE 3; CASPASE 7; HISTONE DEACETYLASE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN P21; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR EZH2; VORINOSTAT;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER TISSUE; CELL CYCLE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; UPREGULATION;

EPIGENETIC; HDAC INHIBITOR; HISTONE DEACETYLASE; TARGETED THERAPY; UROTHELIAL CANCER;

AGED; AGED, 80 AND OVER; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLY(ADP-RIBOSE) POLYMERASES; POLYCOMB REPRESSIVE COMPLEX 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTOME; URINARY BLADDER NEOPLASMS;

EID: 84886292827     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.06.015     Document Type: Article

References (43)

1. Stenzl A., Cowan N.C., De Santis M., et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009, 55:815-825.
2. Dovedi S.J., Davies B.R. Emerging targeted therapies for bladder cancer: A disease waiting for a drug. Cancer Metastasis Rev 2009, 28:355-367.
3. Witt O., Deubzer H.E., Milde T., et al. HDAC family: What are the cancer relevant targets?. Cancer Lett 2009, 277:8-21.
4. Buckley M.T., Yoon J., Yee H., et al. The histone deacetylase inhibitor Belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med 2007, 5:49.
5. Qu W., Kang Y.D., Zhou M.S., et al. Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells. Urol Oncol 2010, 28:648-654.
6. Ozawa A., Tanji N., Kikugawa T., et al. Inhibition of bladder tumor growth by histone deacetylase inhibitor. BJU Int 2010, 105:1181-1186.
7. Vallo S., Xi W., Hudak L., et al. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro. AntiCancer Drugs 2011, 22:1002-1009.
8. Mann B.S., Johnson J.R., Cohen M.H., et al. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12:1247-1252.
9. Seifert H.H., Meyer A., Cronauer M.V., et al. A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder. World J Urol 2007, 25:297-302.
10. Southgate J., Hutton K.A., Thomas D.F., et al. Normal human urothelial cells in vitro: Proliferation and induction of stratification. Lab Invest 1994, 71:583-594.
11. Oya M., Schulz W.A. Decreased expression of p57(KIP2)mRNA in human bladder cancer. Br J Cancer 2000, 83:626-631.
12. Swiatkowski S., Seifert H.H., Steinhoff C., et al. Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp Cell Res 2003, 282:48-57.
13. Rhodes D.R., Kalyana-Sundaram S., Mahavisno V., et al. Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007, 9:166-180.
14. Dyrskjøt L., Kruhøffer M., Thykjaer T., et al. Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathologic classification. Cancer Res 2004, 64:4040-4048.
15. Modlich O., Prisack H.B., Pitschke G., et al. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: Use of cDNA array analysis of gene expression profiles. Clin Cancer Res 2004, 10:3410-3421.
16. Lee J.S., Leem S.H., Lee S.Y., et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol 2010, 28:2660-2667.
17. Lindgren D., Frigyesi A., Gudjonsson S., et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010, 70:3463-3472.
18. Blaveri E., Simko J.P., Korkola J.E., et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005, 11:4044-4055.
19. Sanchez-Carbayo M., Socci N.D., Lozano J., et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006, 24:778-789.
20. Mengual L., Burset M., Ars E., et al. DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers. J Urol 2009, 182:741-748.
21. Dyrskjøt L., Zieger K., Real F.X., et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: A multicenter validation study. Clin Cancer Res 2007, 13:3545-3551.
22. Ozawa A., Tanji N., Kikugawa T., et al. Inhibition of bladder tumor growth by histone deacetylase inhibitor. BJU Int 2009, 105:1181-1186.
23. Huang B.H., Laban M., Leung C.H., et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005, 12:395-404.
24. Weichert W., Röske A., Gekeler V., et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: A retrospective analysis. Lancet Oncol 2008, 9:139-148.
25. Weichert W., Röske A., Gekeler V., et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008, 98:604-610.
26. Weichert W., Röske A., Niesporek S., et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: Specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008, 14:1669-1677.
27. Oehme I., Deubzer H.E., Wegener D., et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009, 15:91-99.
28. Nakagawa M., Oda Y., Eguchi T., et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007, 18:769-774.
29. Marshall G.M., Gherardi S., Xu N., et al. Transcriptional up-regulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene 2010, 29:5957-5968.
30. Zhu P., Martin E., Mengwasser J., et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004, 5:455-463.
31. Schulz W.A. Understanding urothelial carcinoma through cancer pathways. Int J Cancer 2006, 119:1513-1518.
32. Molife L.R., Attard G., Fong P.C., et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) Romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol 2010, 21:109-113.
33. Bradley D., Rathkopf D., Dunn R., et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute trial 6862): Trial results and interleukin-6 analysis: A study by the department of defense prostate cancer clinical Trial Consortium and University of Chicago Phase 2 consortium. Cancer 2009, 115:5541-5549.
34. Ramalingam S.S., Maitland M.L., Frankel P., et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:56-62.
35. Traynor A.M., Dubey S., Eickhoff J.C., et al. Vorinostat (NSC#701852) in patients with relapsed non-small cell lung cancer: A Wisconsin oncology network phase II study. J Thorac Oncol 2009, 4:522-526.
36. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
37. Chatterjee S.J., Datar R., Youssefzadeh D., et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004, 22:1007-1013.
38. Bartkova J., Horejsí Z., Koed K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
39. Qiu L., Burgess A., Fairlie D.P., et al. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 2000, 11:2069-2083.
40. Brandl A., Heinzel T., Krämer O.H. Histone deacetylases: Salesmen and customers in the post-translational modification market. Biol Cell 2009, 101:193-205.
41. Martin M., Kettmann R., Dequiedt F. Class IIa histone deacetylases: Regulating the regulators. Oncogene 2007, 26:5450-5467.
42. Ishikawa F., Miyoshi H., Nose K., et al. Transcriptional induction of MMP-10 by TGF-beta, mediated by activation of MEF2A and down-regulation of class IIa HDACs. Oncogene 2010, 29:909-919.
43. Singh G., Singh S.K., König A., et al. Sequential activation of NFAT and c-Myc transcription factors mediates the TGF-beta switch from a suppressor to a promoter of cancer cell proliferation. J Biol Chem 2010, 285:27241-27250.